{'fraction_non_alphanumeric': 0.030377266046055854, 'fraction_numerical': 0.030377266046055854, 'mean_word_length': 4.884726224783861, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
FRI0076 Ra patients with the highest scores for the 2010 ra classification criteria are less prone to achieve remission after 2 years of follow-up in a very early arthritis clinic

Background Early treatment to achieve remission is the current paradigm in early RA (ERA). Accordingly, the ACR/EULAR recently published both new classification and remission criteria. Presumably, patients with a high score according the classification criteria could have a worse prognosis, but this has not been investigated in a real life setting. Objectives To determine the proportion of ERA patients achieving remission after two years according to the new remission criteria, and to describe factors associated with remission. Methods Patients with arthritis of <16 weeks’ duration were included in an early arthritis cohort from 2004-2010 and followed for 2 years with a comprehensive data collection. Patients were treated according to current clinical practice and not with a structured treat-to-target approach. Patients with 2010 ACR/EULAR RA and 2-year data on the 2010ACR/EULAR remission criteria (Boolean version) were included in this analysis. Frequency of 2-year remission was calculated, and baseline factors were compared in patients achieving vs. not achieving remission by univariate analyses. Results Of 1086 very early arthritis patients, 239 (22.0 %) could be classified as RA at inclusion. Of these, 185 (77.4 %) had completed 2-year follow-up and had data on ACR/EULAR Boolean remission. None of these patients were in remission at inclusion. At 2 years, 41/185 (22.2 %) were in remission. Comparisons of selected baseline factors between patients in vs. not in remission are shown in the table. Conclusions Only 22 % of patients with ERA were in remission after 2 years. High scores for the classification criteria (9 or 10 points) were associated with lower frequency of remission. Our findings confirm the need for a treat-to-target approach with careful monitoring in this patient population. Disclosure of Interest None Declared